Ignite Creation Date:
2024-05-06 @ 7:55 PM
Last Modification Date:
2024-10-26 @ 3:16 PM
Study NCT ID:
NCT06182891
Status:
COMPLETED
Last Update Posted:
2023-12-27
First Post:
2023-11-07
Brief Title:
Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic Nephropathy
Sponsor:
The Affiliated Hospital of Xuzhou Medical University
Organization:
The Affiliated Hospital of Xuzhou Medical University
Study Overview
Official Title:
Department of Pharmacy the Affiliated Hospital of Xuzhou Medical University
Status:
COMPLETED
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the real-world observational prospective study is to access the renoprotective effects of dulaglutide as well as to explore corresponding mechanisms in patients with Type 2 Diabetic Nephropathy
Detailed Description:
Related studies have found that Glucagon-like peptide-1 GLP-1 receptors are localized on a variety of tissues and cell types in addition to pancreatic β-cells and GLP-1 and GLP-1 receptor agonists can exert diverse effect on multiple organs and tissues with pleiotropic potential physiological pathophysiological as well as pharmacological implications Multiple clinical trials suggest that GLP-1 receptor agonists can exert renoprotective effects and persuasively inhibit the progression of kidney disease in type 2 diabetic patients The beneficial effects of GLP-1 receptor agonists on Type 2 Diabetic Nephropathy independent of their hypoglycemic ability might are mediated by anti-oxidative stress anti-inflammatory and natriuresis properties However it is not clear whether the above-mentioned properties are involved in the EMT process of renal tubular epithelial cells
All participants meeting all eligibility criteria received routine medical consultations During routine medical visits patients were randomized into two groups 1071 to receive a total duration of 12 months of hypoglycemic therapy - dulaglutide plus other hypoglycemic agents not including GLP-1 receptor agonists intervention group and other hypoglycemic agents not including GLP-1 receptor agonists control group A random number method was applied for grouping in this study Dulaglutide and other hypoglycemic agents were administered according to the drug package insert Of course the investigators decided on other background treatments for hypertension hyperlipidemia or cardiovascular-related risk factors based on the latest guidelines throughout the trial
All participants meeting all eligibility criteria received routine medical consultations During routine medical visits patients were randomized into two groups 1071 to receive a total duration of 12 months of hypoglycemic therapy - dulaglutide plus other hypoglycemic agents not including GLP-1 receptor agonists intervention group and other hypoglycemic agents not including GLP-1 receptor agonists control group A random number method was applied for grouping in this study Dulaglutide and other hypoglycemic agents were administered according to the drug package insert Of course the investigators decided on other background treatments for hypertension hyperlipidemia or cardiovascular-related risk factors based on the latest guidelines throughout the trial
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None